PT - JOURNAL ARTICLE AU - Wu, Hao AU - He, Xiaona AU - Cao, Yu AU - Gao, Wei TI - Adverse events affecting recovery from seasonal influenza vaccination in the hypertensive population: A population-based pharmacovigilance analysis AID - 10.1101/2024.09.03.24313030 DP - 2024 Jan 01 TA - medRxiv PG - 2024.09.03.24313030 4099 - http://medrxiv.org/content/early/2024/09/04/2024.09.03.24313030.short 4100 - http://medrxiv.org/content/early/2024/09/04/2024.09.03.24313030.full AB - Seasonal influenza vaccination is crucial for preventing influenza and its complications. Data from the U.S. Vaccine Adverse Event Reporting System (VAERS) indicate a higher proportion of adverse events (AEs) after influenza vaccination in hypertensive people. However, there is limited evidence on AEs in hypertensive people following seasonal influenza vaccination. We collected a total of 4647 individuals on seasonal influenza vaccination and 6380 AEs from VAERS for hypertensive people aged 18 years or older from 1 January 2013 to 23 June 2023. We conducted propensity score matching (PSM) by adjusting for the demographic characteristics of the seasonal influenza-vaccinated hypertensive population and the season of onset. Cox regression analysis was used to calculate the risk ratio of reported adverse events (AEs) that affected recovery after seasonal influenza vaccination. Most AEs were nonserious and occurred within 48 hours. The most common AEs were general disorders and administration site conditions (therapeutic and non-therapeutic responses, inflammation) and musculoskeletal and connective tissue disorders (musculoskeletal and connective tissue pain and discomfort, bursal disorders, joint-related signs, and symptoms). All three types of seasonal influenza vaccines were associated with injection site reactions (47.07% trivalent influenza vaccine [TIA], hazard ratio, HR 2.04, 95% confidence interval, CI 1.22–3.40; 20.00% quadrivalent influenza vaccine [QIA], HR 2.81, 95% CI, 1.81–4.37; 67.48% influenza vaccine, unknown manufacturer [FLUX], HR 2.83, 95% CI, 1.12–7.15) and were the AEs affecting the largest proportion of delayed recoveries in the hypertensive population. Potential AEs following seasonal influenza vaccination may affect the recovery of the hypertensive population. The majority of AEs reported were general disorders, predominantly injection site reactions, and nonserious.Competing Interest StatementThe authors have declared no competing interest.Funding StatementYesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No ethical approval was required as this paper is based on publicly available data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe raw data used in this study are available at https://vaers.hhs.gov/data/datasets.html. https://vaers.hhs.gov/data/datasets.html.